Recombinant Human Urokinase-Type Plasminogen Activator is produced with our mammalian expression system in human cells. The target protein is expressed with sequence (Ser21-Leu431) of Human PLAU fused with a polyhistidine tag at the C-terminus.
纯度
> 95 % as determined by reducing SDS-PAGE.
过滤
0.2 μm filtered
内毒素水平
Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test
PLAU
宿主: 大鼠
宿主: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 90 % as determined by HPLC
限制
仅限研究用
状态
Liquid
溶解方式
It is not recommended to reconstitute to a concentration less than 100 μg/mL. Dissolve the lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
缓冲液
Supplied as a 0.2 μm filtered solution of 20 mM HEPES, 150 mM NaCl, 2 mM CaCl, 10 % Glycerol, pH 7.5.
注意事项
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
储存条件
-80 °C
储存方法
Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles.
Recombinant Human Urokinase-Type Plasminogen Activator is a serine protease, which specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. Urokinase-Type Plasminogen Activator is a potent marker of invasion and metastasis in many human cancers associated with breast, colon, stomach, bladder, brain, ovary and endometrium. Human Urokinase-Type Plasminogen Activator is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide residues. The single chain molecule is processed into a disulfide-linked two-chain molecule. There exists two forms A chain, the long A chain contains an EGF-like domain that is responsible for binding of the uPA receptor. The B chain corresponds to the catalytic domain. Alternative Names: Urokinase-Type Plasminogen Activator, U-Plasminogen Activator, uPA, PLAU